Biotechnology company Compass Pathways plc (Nasdaq:CMPS) announced on Tuesday that its COMP360 psilocybin formulation met the primary endpoint in the Phase 3 COMP006 trial, demonstrating a statistically significant and clinically meaningful reduction in Montgomery-Åsberg Depression Rating Scale scores at Week 6 versus a 1 mg comparator.
Two 25 mg doses delivered three weeks apart produced a mean treatment difference of −3.8 points (p
Palisade Bio makes Clinical Advisory Board appointment
Curasight announces presentation at TD Cowen's 46th Annual Health Care Conference in Boston
Celltrion data show subcutaneous infliximab restores disease control after treatment interruption
Cambridge Cognition expands into India through Ivory commercialisation agreement
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer
MetaVia secures global patent protection for DA-1726
MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy
AstraZeneca reports positive Phase III results for BREZTRI in uncontrolled asthma
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial